Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 24, Issue 4 (July 2022) 24, 390–397; 10.4103/aja202171

Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis

Jun-Jie Zhang1,2, Xiao Shi3, Ting Wu4, Meng-Da Zhang1,2, Jin Tang1, Guang-Ming Yin1, Zhi Long1, Le-Ye He1, Lin Qi2, Long Wang1

1 Department of Urology, The Third Xiangya Hospital, Central South University, Changsha 410008, China
2 Department of Urology, Xiangya Hospital, Central South University, Changsha 410013, China
3 Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha 410013, China
4 Department of Cardiovascular Medicine, The Third Xiangya Hospital, Central South University, Changsha 410013, China

Correspondence: Dr. L Wang (wanglong@csu.edu.cn)

Date of Submission 18-Dec-2020 Date of Acceptance 02-Sep-2021 Date of Web Publication 29-Oct-2021

Abstract

Postfinasteride syndrome (PFS) is a term coined to characterize a constellation of reported undesirable sexual, physical, and neuropsychiatric side effects. In the present study, we conducted the meta-analysis to demonstrate whether the use of 5α-reductase inhibitors (5ARIs) increases the risk of PFS-like adverse effects. A search of studies published until May 10, 2020, was performed using PubMed, EMBASE, and the Cochrane Library. We included randomized controlled trials with at least one comparison between male patients receiving 5ARIs versus placebo for the treatment of benign prostatic hyperplasia (BPH) or androgenetic alopecia (AGA), and identified 34 studies from 28 articles that met our eligibility criteria. In the random-effects model, the overall use of 5ARIs exhibited a 1.87-fold risk of PFS-like adverse effects during the trial (95% confidence interval [CI]: 1.64–2.14). Regarding specific types of adverse effects, the use of 5ARIs had a 1.89-fold risk of sexual adverse effects (95% CI: 1.74–2.05) and was associated with an increased risk of physical adverse effects (relative risk [RR]: 1.31, 95% CI: 0.80–2.15), albeit without statistical significance. This meta-analysis helped to better define the adverse effects caused by 5ARIs. We concluded that the overall use of 5ARIs significantly increased the risk of PFS-like adverse effects in men with AGA or BPH during treatment. Enhanced awareness of and education on the PFS-like adverse effects are necessary for clinicians.

Keywords: 5α-reductase inhibitors; adverse effects; androgenetic alopecia; benign prostatic hyperplasia; postfinasteride syndrome

Full Text | PDF |

 
Browse:  85
 
Copyright 1999-2017  Shanghai Materia Medica, Shanghai Jiao Tong University.  All rights reserved